Here are the key details about the GARDEL study, presented just this week by Pedro Cahn at the European AIDS Clinical Society meeting, or EACS:
It was a common scene several years ago throughout Fort Lauderdale. Clinic parking lots were filled with cars bearing license plates from Georgia, Tennessee, Pennsylvania and Kentucky. When one vehicle pulled out it was immediately replaced by another, and another after that. These were not snow birds seeking sun and warm temperatures, but rather people trafficking opiates. They shopped at dozens of pain management clinics dotting Broward County, buying hundreds of OxyContin (oxycodone) to take home and sell. At one point, Broward County had more so-called "pill mills" than McDonald's, and a few local physicians prescribed more of the narcotic than the rest of the country combined.
In case you didn't know, "MODERN" is the clever name for the "Maraviroc Once-daily with Darunavir Enhanced by Ritonavir in a New regimen" trial, which compared TDF/FTC to maraviroc, both with boosted darunavir.
You know how to make an ID/HIV specialist angry? Frustrated? Sigh loudly?
Tell a clinical anecdote that involves "late" presentation of HIV diagnosis, in particular someone who has been seeking medical care for various ailments for months or even years without getting tested.
HIV researchers can now submit their abstracts to the 2014 Conference on Retroviruses and Opportunistic Infections -- or "CROI."
(It rhymes with "soy," as in "soy sauce"; or, if you prefer, "oy," as in "oy vey.")
Further details here. General submission for abstracts closes on October 8.
The recently approved once-daily integrase inhibitor dolutegravir is now in pharmacies and, like every new HIV drug, the price -- around $14k/year -- has generated some controversy.
As anticipated, the FDA approved dolutegravir today for HIV treatment, the third integrase inhibitor now available.
This was about as surprising as the arrival of Royal Baby Prince George. We knew dolutegravir was coming soon, just not exactly when or what it would be named.
Part two of a two-part conversation with research advocate Richard Jefferys, who coordinates the Basic Science Vaccines and Prevention Project at Treatment Action Group in New York City.
Part one of a two-part conversation with research advocate Richard Jefferys, who coordinates the Basic Science Vaccines and Prevention Project at Treatment Action Group in New York City.
If I hear or read another proclamation about the "HIV treatment cascade" and the need for more research to understand engagement in care, I am going to scream! There, I said it. It seems this cascade -- described initially by Laura Cheever at HRSA and most recently and formally by Gardner and colleagues -- has taken the HIV world by storm. It has captivated the field of HIV practitioners, advocates, researchers and scientists and peppers nearly every lecture at conferences and conversation at the watercooler. But why?